These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 18043758

  • 1. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
    Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE.
    PLoS One; 2007 Nov 28; 2(11):e1251. PubMed ID: 18043758
    [Abstract] [Full Text] [Related]

  • 2. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
    Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.
    J Virol; 2006 Nov 28; 80(22):10957-71. PubMed ID: 16956950
    [Abstract] [Full Text] [Related]

  • 3. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
    Urano E, Timilsina U, Kaplan JA, Ablan S, Ghimire D, Pham P, Kuruppu N, Mandt R, Durell SR, Nitz TJ, Martin DE, Wild CT, Gaur R, Freed EO.
    J Virol; 2019 Mar 15; 93(6):. PubMed ID: 30567982
    [Abstract] [Full Text] [Related]

  • 4. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.
    Antimicrob Agents Chemother; 2016 Jan 15; 60(1):190-7. PubMed ID: 26482309
    [Abstract] [Full Text] [Related]

  • 5. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
    Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.
    Retrovirology; 2011 Dec 07; 8():101. PubMed ID: 22151792
    [Abstract] [Full Text] [Related]

  • 6. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
    Antimicrob Agents Chemother; 2007 Oct 07; 51(10):3574-81. PubMed ID: 17638699
    [Abstract] [Full Text] [Related]

  • 7. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
    Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.
    J Virol; 2009 May 07; 83(10):4884-94. PubMed ID: 19279107
    [Abstract] [Full Text] [Related]

  • 8. Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation.
    Neyret A, Gay B, Cransac A, Briant L, Coric P, Turcaud S, Laugâa P, Bouaziz S, Chazal N.
    Antiviral Res; 2019 Apr 07; 164():162-175. PubMed ID: 30825471
    [Abstract] [Full Text] [Related]

  • 9. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M, Kollmann TR, Raker C, Kim A, Yurasov S, Tudor R, Wiltshire H, Goldstein H.
    Antimicrob Agents Chemother; 1997 Sep 07; 41(9):1880-7. PubMed ID: 9303378
    [Abstract] [Full Text] [Related]

  • 10. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
    Martin DE, Salzwedel K, Allaway GP.
    Antivir Chem Chemother; 2008 Sep 07; 19(3):107-13. PubMed ID: 19024627
    [Abstract] [Full Text] [Related]

  • 11. A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
    Ghimire D, Kc Y, Timilsina U, Goel K, Nitz TJ, Wild CT, Gaur R.
    Retrovirology; 2021 Apr 09; 18(1):9. PubMed ID: 33836787
    [Abstract] [Full Text] [Related]

  • 12. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
    Zhao Y, Gu Q, Morris-Natschke SL, Chen CH, Lee KH.
    J Med Chem; 2016 Oct 13; 59(19):9262-9268. PubMed ID: 27676157
    [Abstract] [Full Text] [Related]

  • 13. Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
    Lin Z, Cantone J, Lu H, Nowicka-Sans B, Protack T, Yuan T, Yang H, Liu Z, Drexler D, Regueiro-Ren A, Meanwell NA, Cockett M, Krystal M, Lataillade M, Dicker IB.
    PLoS Pathog; 2016 Nov 13; 12(11):e1005990. PubMed ID: 27893830
    [Abstract] [Full Text] [Related]

  • 14. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
    Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO.
    Virology; 2010 Apr 25; 400(1):137-44. PubMed ID: 20172577
    [Abstract] [Full Text] [Related]

  • 15. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, Moreno ME, Rivera JM, Ronquillo RE, Sloan B, Black PL.
    PLoS One; 2007 Aug 01; 2(7):e655. PubMed ID: 17668043
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A, van Maarseveen NM, Pokorná J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M.
    Retrovirology; 2011 Aug 24; 8():70. PubMed ID: 21864346
    [Abstract] [Full Text] [Related]

  • 17. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
    Martin DE, Blum R, Doto J, Galbraith H, Ballow C.
    Clin Pharmacokinet; 2007 Aug 24; 46(7):589-98. PubMed ID: 17596104
    [Abstract] [Full Text] [Related]

  • 18. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
    Kazennova EV, Vasil'ev AV, Bobkova MR.
    Vopr Virusol; 2010 Aug 24; 55(3):37-41. PubMed ID: 20608080
    [Abstract] [Full Text] [Related]

  • 19. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
    Margot NA, Gibbs CS, Miller MD.
    Antimicrob Agents Chemother; 2010 Jun 24; 54(6):2345-53. PubMed ID: 20308382
    [Abstract] [Full Text] [Related]

  • 20. Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
    Nowicka-Sans B, Protack T, Lin Z, Li Z, Zhang S, Sun Y, Samanta H, Terry B, Liu Z, Chen Y, Sin N, Sit SY, Swidorski JJ, Chen J, Venables BL, Healy M, Meanwell NA, Cockett M, Hanumegowda U, Regueiro-Ren A, Krystal M, Dicker IB.
    Antimicrob Agents Chemother; 2016 Jul 24; 60(7):3956-69. PubMed ID: 27090171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.